Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study

被引：2

作者：

Gallois, C. ^{[1
]}

Elez Fernandez, M. E. ^{[2
]}

Auclin, E. ^{[3
]}

Bergen, E. S. ^{[4
]}

Pernot, S. ^{[5
]}

Higue, J. ^{[6
]}

Trouilloud, I. ^{[7
]}

Touchefeu, Y. ^{[8
]}

Turpin, A. ^{[9
]}

Mazard, T. ^{[10
]}

Pilla, L. ^{[1
]}

Cuissy, S. ^{[11
]}

Wookey, V. ^{[12
]}

Perret, A. ^{[13
]}

Melchior, C. ^{[14
]}

Artru, P. ^{[15
]}

Stintzing, S. ^{[16
]}

Dubreuil, O. ^{[17
]}

Tougeron, D. ^{[18
]}

Taieb, J. ^{[19
]}

机构：

[1] Hop Europeen Georges Pompidou, AP HP, Digest Oncol Dept, Paris, France

[2] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[3] Hop Europeen Georges Pompidou, AP HP, Oncol Dept, Paris, France

[4] Univ Kliniken MedUni Wien AKH Wien, Div Oncol, Dept Med 1, Vienna, Austria

[5] Inst Bergonie, Digest Med Oncol Unit, Bordeaux, France

[6] Inst Univ Canc Toulouse Oncopole, Haute Garonne, Toulouse, France

[7] Hop St Antoine, Med Oncol Dept, Paris, France

[8] CHU Nantes, Digest Oncol, Hotel Dieu, Nantes, France

[9] CHU Lille, Dept Med Oncol, Lille, France

[10] Inst Canc Montpellier, Med Oncol, Montpellier, France

[11] CHU Rouen Normandie, Seine Maritime, Rouen, France

[12] Mayo Clin, Dept Oncol, Rochester, MN USA

[13] Inst Gustave Roussy, Digest Oncol Dept, Villejuif, France

[14] Ctr Leon Berard, Digest Oncol Dept, Lyon, France

[15] Hop Prive Jean Mermoz, GI Oncol Dept, Lyon, France

[16] Charite Univ Med Berlin, Hematol Oncol & Canc Immunol CCM Dept, Berlin, Germany

[17] Gh Diaconesses Croix St Simon, Med Oncol, Paris, France

[18] CHU Poitiers, Dept Gastroenterol & Hepatol, Jean Bernard Hop, Poitiers, France

[19] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1816

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

625P

引用

页码：S446 / S446

页数：1

共 50 条

[21] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)
Chiu, C-F.
Yeh, Y-M.
Yeh, K-H.
Desai, J.
Price, T. J.
Tebbutt, N.
Tabernero, J.
Velez, L.
Trevino, T. L.
Grothey, A.
Yaeger, R.
Gollerkeri, A.
Maharry, K.
Kopetz, S.
ANNALS OF ONCOLOGY, 2020, 31 : S1276 - S1276
[22] BRAF V600E confers resistance to cetuximab or panitumumab metastatic colorectal cancer
Di Nicolantonio, F.
Martini, M.
Molinari, F.
Bianchi, A. Sartore
Arena, S.
Saletti, P.
Mazzucchelli, L.
Frattini, M.
Siena, S.
Bardelli, A.
EJC SUPPLEMENTS, 2008, 6 (12): : 81 - 81
[23] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
Shahjehan, F.
Kamatham, S.
Chandrasekharan, C.
Kasi, P. M.
DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
[24] Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer
Giuliani, Jacopo
Mantoan, Beatrice
Bonetti, Andrea
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 199 - 202
[25] BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
Kotani, Daisuke
Bando, Hideaki
Taniguchi, Hiroya
Masuishi, Toshiki
Komatsu, Yoshito
Yamaguchi, Kensei
Nakajima, Takako
Satoh, Taroh
Nishina, Tomohiro
Esaki, Taito
Nomura, Shogo
Takahashi, Koji
Iida, Shinobu
Matsuda, Seiko
Motonaga, Shinya
Fuse, Nozomu
Sato, Akihiro
Fujii, Satoshi
Ohtsu, Atsushi
Ebi, Hiromichi
Yoshino, Takayuki
ESMO OPEN, 2020, 5 (01)
[26] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
Shuosha Li
Huabin Hu
Dong Ding
Youwen Zhu
Jin Huang
Advances in Therapy, 2021, 38 : 1650 - 1659
[27] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
Li, Shuosha
Hu, Huabin
Ding, Dong
Zhu, Youwen
Huang, Jin
ADVANCES IN THERAPY, 2021, 38 (03) : 1650 - 1659
[28] BRAF (V600E) mutant metastatic colorectal cancer: What is the role of the antiangiogenic therapy in a real-world setting?
Lago, Nieves Martinez
Montes, Ana Fernandez Fernandez
Rua, Marta Covela
Vazquez, Elena Brozos
De La Camara, Juan Cruz
Fernandez, Monica Jorge
Cousillas, Antia
Mendez Mendez, Jose Carlos
Campos, Marta Carmona
Reinoso, Carlos Romero
Villarroel, Paula Gonzalez
Insua, Yolanda Vidal
Martin, Elena Gallardo
Grana, Begona
Rivera, Francisca Vazquez
Augusto, Maria Luz Pellon
Quintero Aldana, Guillermo Alfonso
Lopez, Margarita Reboredo
Folgar, Sonia Candamio
Fernandez, Mercedes Salgado
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset
Germani, M. M.
Vetere, G.
Santamaria, F.
Intini, R.
Ghelardi, F.
Bensi, M.
Boccaccino, A.
Minelli, A.
Carullo, M.
Ciraci, P.
Passardi, A.
Santucci, S.
Giampieri, R.
Persano, M.
Fenocchio, E.
Puccini, A.
Lonardi, S.
Pietrantonio, F.
Salvatere, L.
Cremolini, C.
ESMO OPEN, 2024, 9 (04)
[30] Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab
Zwart, Koen
van Nassau, Sietske C. M. W.
van der Baan, Frederieke H.
Koopman, Miriam
Snaebjornsson, Petur
van Gestel, Anna J.
Vink, Geraldine R.
Roodhart, Jeanine M. L.
BRITISH JOURNAL OF CANCER, 2024, 131 (01) : 110 - 116

← 1 2 3 4 5 →